Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Medical Dermatology Specialists
With
DUSA Pharmaceuticals, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Received solid organ transplant
3-24 months post-transplant (any number of transplant)
Time interval of at least 6 days duration where complications such as rejection episodes, viral infections, surgical interventions and therapies with mono or polyclonal antibodies are ruled out by the transplant team.
No prior history of NMSC in the treatment fields
No AK/Bowen's disease in the treatment fields within the last 3 months.
Moderate to severe sun damage
Be willing to forego other interventions in the treatment fields than the ones approved by the investigator that would interfere with the protocol or evaluation of the study medication
You may not be if
Patients with Fitzpatrick's scale skin type IV-VI
Cutaneous photosensitivity to wavelengths of 400-450 nm, porphyria or known allergies to porphyrins
Known sensitivity to any of the components of the Levulan® Kerastick® for Topical Solution
Prior use of topical or systemic therapies that might interfere with the evaluation of the study medication during the study, within a 3 month washout period from the time of the screening visit
Unable to return for follow-up visits and tests
Any condition or situation which in the Investigator's opinion may put the subject at significant risk, could confound the study results, or could interfere significantly with the subject's participation in the study
